drugset / Trial / NCT05205850
A Study of RC118 in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
In Phase I, This study will explore the tolerability and safety of RC118 in patients with locally advanced unresectable or metastatic malignant solid tumors with positive Claudin 18.2 expression, and determine the maximum tolerated dose (MTD) and the recommended dose in phase II clinical trials (RP2D); In Phase IIa, to explore the clinical effectiveness and safety of long-term use of RC118 at RP2D doses for patients with different tumor types。
Timeline
- Start
- 2022-03-03
- Primary completion
- 2025-09-30
- Completion
- 2025-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RC118-ADC | Unknown | 0.25 mg/kg | — |
| Subject | RC118-ADC | Unknown | 0.5 mg/kg | — |
| Subject | RC118-ADC | Unknown | 1 mg/kg | — |
| Subject | RC118-ADC | Unknown | 1.5 mg/kg | — |
| Subject | RC118-ADC | Unknown | 2 mg/kg | — |
| Subject | RC118-ADC | Unknown | 2.5 mg/kg | — |
| Subject | RC118-ADC | Unknown | 3 mg/kg | — |